Learn about lung metastases from breast cancer, stage IV treatment options, and advanced treatment pathways in Germany with coordinated support through TIG.
Breast cancer is a malignant tumor arising from the epithelial lining of the breast ducts or lobules. It develops when genetic alterations disrupt normal cell cycle regulation, allowing abnormal cells to proliferate uncontrollably and invade surrounding tissue. While many patients are diagnosed at an early stage through screening programs, some tumors demonstrate aggressive biological behavior and may spread beyond the breast and regional lymph nodes to distant organs, leading to metastatic breast cancer, such as breast cancer with lung mets.
For patients facing advanced disease, various breast cancer treatment options in Germany are available, ranging from systemic therapies to targeted interventions aimed at controlling disease progression and improving quality of life. According to Global Cancer Statistics 2020, female breast cancer accounted for 2,261,419 (11.7%) of all new cancer cases worldwide and 684,996 (6.9%) of cancer deaths in 2020 [1]. These figures confirm breast cancer as the most commonly diagnosed cancer in women worldwide. When detected at a localized stage, outcomes are favorable, and early stage breast cancer survival rates remain significantly high. However, once distant metastases develop, prognosis changes considerably.
The SEER Cancer Stat Facts report that the 5-year relative survival rate for women with distant-stage breast cancer is 31%, based on cases diagnosed from 2014 through 2020 [2]. Among patterns of distant spread, pulmonary involvement is common. A population-based SEER study reported that 6,516 patients were diagnosed with lung metastases, accounting for 30.4% of patients with metastatic breast cancer at initial presentation [3]. Patients seeking structured stage IV breast cancer treatment in Germany often evaluate advanced care pathways within German oncology centers, where cases are reviewed in multidisciplinary tumor boards.
Prof. Vogl is recognized as an expert in image-guided interventional oncology and embolization therapies, and Prof. Gansauge is known for expertise in regulated cellular immunotherapy programs, including Immunotherapy Dendritic Cell Therapy for breast cancer. This coordinated approach within Germany’s healthcare system provides access to some of the best breast cancer treatment centers, guided by experienced German specialists, including experienced oncologists specializing in metastatic breast cancer.
Lung metastases occur when malignant breast cancer cells disseminate through vascular or lymphatic pathways and colonize pulmonary tissue. The lungs are particularly susceptible because circulating tumor cells become trapped within the extensive capillary network. Once lodged in lung tissue, cancer cells interact with the local microenvironment, enabling survival, proliferation, and eventual formation of metastatic nodules.
Radiologic evaluation plays a central role in diagnosis. Advanced diagnostics, including CT scans, MRI, and PET scans, are used to determine the size, number, and distribution of metastatic lesions. Imaging also helps distinguish metastatic breast cancer from primary lung malignancies or inflammatory processes. Histopathologic confirmation may be required when imaging findings are inconclusive.
Metastatic spread represents systemic disease, meaning treatment strategies must address both pulmonary lesions and potential involvement of other organs. Comprehensive cancer treatment planning is therefore essential, integrating systemic therapy, imaging surveillance, and, in selected cases, interventional oncology.
Standard Systemic Therapy and Clinical Management of Stage IV Breast Cancer
Systemic therapy remains the cornerstone of stage IV breast cancer treatment. Therapeutic decisions are guided by tumor biology, including hormone receptor status and HER2 expression, as well as prior treatment exposure and overall patient condition. Hormone receptor–positive metastatic disease is commonly managed with endocrine therapy combined with targeted agents. HER2-positive disease is typically treated with HER2-directed monoclonal antibodies integrated with chemotherapy. Triple-negative metastatic breast cancer often requires chemotherapy, with immunotherapy considered in selected cases.
The primary objectives of systemic treatment are disease control, symptom management, and maintenance of quality of life. Regular monitoring with CT scans, MRI, and PET scans allows clinicians to assess pulmonary lesion response and detect disease progression. Within structured cancer treatment in Germany programs, systemic therapy may be complemented by localized interventions when dominant pulmonary metastases demonstrate progression despite ongoing treatment.
Multidisciplinary tumor board evaluation within leading German oncology centers ensures individualized sequencing of therapies. This structured coordination expands access to new and innovative treatment options for breast cancer within regulated clinical programs.
TACP treatment for Lung metastases from breast cancer is an interventional oncology technique designed to deliver high concentrations of chemotherapy directly into tumor-feeding vessels supplying metastatic lung lesions. By increasing intratumoral drug exposure while limiting systemic circulation, TACP aims to enhance localized cytotoxic effect in carefully selected patients.
The procedure is performed under fluoroscopic guidance in specialized interventional radiology units equipped with the latest medical technology in Germany. Through minimally invasive vascular access, a microcatheter is advanced selectively into vessels supplying the metastatic deposit. Once precise positioning is confirmed, chemotherapy is infused in a controlled and localized manner to maximize concentration within tumor tissue.
Careful pre-procedural assessment includes imaging review, vascular mapping, pulmonary function evaluation, and multidisciplinary tumor board discussion. During infusion, continuous imaging guidance ensures protection of surrounding healthy lung parenchyma. Post-procedural monitoring evaluates hemodynamic stability and potential transient symptoms.
Follow-up imaging is performed to assess radiologic response and determine the need for additional sessions. The cost of TACP therapy in Germany typically ranges between €8,000 and €9,000 per session. This interventional approach is considered in selected cases and is not part of standard international first-line treatment guidelines.
TPCE treatment for Lung metastases from breast cancer combines selective chemotherapy infusion with controlled embolization of tumor-associated vessels. After localized chemotherapeutic delivery, embolic materials are introduced to block the blood flow to metastatic tissue, thereby prolonging intratumoral drug retention and inducing ischemic tumor stress.
This dual-mechanism approach requires meticulous superselective catheter placement to preserve surrounding pulmonary structures. High-resolution angiographic imaging enables precise visualization of tumor vascular supply. The embolization component is carefully calibrated to avoid excessive compromise of healthy lung tissue while maximizing therapeutic impact.
Eligibility for TPCE is determined through comprehensive imaging assessment and evaluation of cardiopulmonary function. Multidisciplinary tumor board review ensures appropriate patient selection within regulated oncology programs. Post-treatment follow-up includes imaging reassessment and clinical monitoring. The cost of TPCE therapy in Germany typically ranges between €8,000 and €9,000 per session. This interventional approach is considered in selected cases and is not part of standard international first-line treatment guidelines.
Immunotherapy Dendritic Cell Therapy for breast cancer in Germany represents a personalized immune activation strategy integrated into regulated oncology programs. The process begins with comprehensive medical evaluation assessing immune competence, organ function, tumor subtype, and prior treatment exposure. Suitability is determined through multidisciplinary tumor board discussion.
Following approval, a controlled blood sample is collected to isolate immune cells (Monocytes). These cells are transferred to an EU GMP certified laboratory, where strict regulatory standards govern isolation, differentiation, maturation, sterility testing, and quality control. Monocytes are cultured and transformed into mature dendritic cells capable of presenting tumor-associated antigens to T lymphocytes.
During laboratory preparation, dendritic cells are exposed to tumor-specific antigens derived from the patient’s cancer profile, generating a personalized dendritic cell vaccine. Before administration, the cellular product undergoes comprehensive sterility, viability, and identity testing. The vaccine is administered intradermally according to an individualized schedule, followed by structured clinical and immune monitoring. The cost of Immunotherapy Dendritic Cell Therapy in Germany is €27,000 which includes laboratory processing and vaccine preparation.
Ongoing Clinical Research and New Clinical Trials for Breast Cancer in Germany
Clinical research continues to expand therapeutic strategies for metastatic breast cancer, including patients with pulmonary involvement. Access to new clinical trials for breast cancer in Germany may be available for eligible patients following strict inclusion criteria and multidisciplinary review.
Research initiatives evaluate antibody-drug conjugates, combination immunotherapy strategies, molecularly targeted agents, and cellular immune approaches. These programs aim to expand new and innovative treatment options for breast cancer within carefully regulated clinical frameworks.
Enrollment in clinical trials requires comprehensive evaluation of tumor biology, prior therapies, organ function, and performance status. Participation provides access to investigational therapies while maintaining structured safety oversight within Germany’s healthcare system.
Management of lung metastases from breast cancer requires realistic expectations and individualized assessment. While localized interventional therapies such as TACP and TPCE may provide regional control in selected cases, they do not replace systemic therapy in the context of widespread metastatic disease. Careful patient selection remains essential to balance potential benefit with procedural risk.
Immune-based strategies depend on adequate immune responsiveness and may be influenced by tumor-mediated immunosuppressive mechanisms. Scientific literature describing dendritic-cell–based therapeutic cancer vaccines highlights variability in immune activation depending on tumor microenvironment and host immune status [4]. Therefore, immune-based interventions must be integrated thoughtfully within comprehensive treatment planning.
Multidisciplinary tumor board evaluation within German oncology centers ensures coordinated sequencing of systemic therapy, interventional oncology, and immune-based strategies. Structured clinical assessment reduces overtreatment risk and supports evidence-based decision-making.
International Patient Support through Treatment in Germany
Access to advanced management for Lung Metastases from Breast Cancer involves more than clinical decision-making; it requires careful logistical coordination, especially for international patients seeking specialized therapies such as TACP, TPCE or Immunotherapy Dendritic cell therapy. Through Treatment in Germany (TIG), medical documentation is reviewed in advance to facilitate appropriate specialist referral and structured treatment planning within experienced oncology centers. This pre-evaluation by the treating physician helps align the patient’s clinical condition with available therapeutic options before travel arrangements are finalized.
Treatment in Germany (TIG) at www.treatmentingermany.de provides comprehensive logistical assistance, including hospital coordination, appointment scheduling, travel planning, and medical visa support when required. By organizing these administrative components in advance, patients can focus on clinical evaluation and multidisciplinary consultation upon arrival. Individuals considering advanced and Innovative treatment approaches may get a free consultation with TIG (Treatment in Germany) to receive structured guidance and coordinated access to specialized cancer programs in Germany.
1- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660. Open Access.
2- National Cancer Institute. SEER Cancer Stat Facts: Female Breast Cancer. Surveillance, Epidemiology, and End Results Program. Public Registry.
3- Wu Q, Li J, Zhu S, et al. Breast Cancer Patients with Lung Metastases at Initial Diagnosis: A Population-Based Study. PeerJ. 2020;8:e8298. doi:10.7717/peerj.8298. Open Access.
4- Palucka K, Banchereau J. Dendritic-Cell–Based Therapeutic Cancer Vaccines. Immunity. 2013;39(1):38–48. doi:10.1016/j.immuni.2013.07.004. PMC Free Article.
5- Cardoso F, et al. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer. Ann Oncol. 2018;29(8):1634–1657. PMC Free Article.
🌍Why Patients Worldwide Prefer Our Medical Services in Germany – Key Benefits Explained:
They are secondary tumors in the lungs that originate from primary breast cancer cells and indicate systemic disease spread.
It is generally treated as a chronic systemic condition focused on disease control and quality of life.
It is a personalized immune-based therapy designed to support cancer marker recognition.
They are among the most frequent distant metastatic sites identified in advanced disease.
Yes, structured oncology programs may offer new and innovative treatment options for breast cancer based on clinical evaluation.
No, it complements systemic therapy but does not replace it in widespread disease.
Eligible patients may be considered for new clinical trials for breast cancer in Germany.
It has been investigated in several solid tumors in research settings.
Yes. International patients can access innovative treatments for breast cancer in Germany, with full logistical coordination provided by TIG (Treatment in Germany) www.treatmentingermany.de covering appointments, travel, medical visa assistance (if needed), and follow-up care.
Germany has many highly experienced oncologists and specialized cancer centers known for advanced diagnostics and personalized treatment approaches. The “best” cancer specialist depends on the specific cancer type and treatment needs. Some of the most recognized cancer experts include professors working at leading hospitals such as Charité University Hospital (Berlin), University Hospital Heidelberg, University Hospital Munich (LMU), and Frankfurt University Hospital.
Kindly complete the form below, and our dedicated team will reach out to you promptly. We look forward to connecting with you soon!
Trierer Straße, 56072 Koblenz, Germany
Our benefits:
.webp)
 (1).webp)
.webp)
 (1).webp)
